SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
about
The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysisComputational methods in drug discoveryNSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesisTherapeutic value of quinazoline-based compounds in prostate cancer.YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical modelsAAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis modelExploring the role of mitochondrial UQCRB in angiogenesis using small molecules.Mitochondrial UQCRB regulates VEGFR2 signaling in endothelial cells.Synergic antitumor effect of SKLB1002 and local hyperthermia in 4T1 and CT26.PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling.WMJ-S-001, a novel aliphatic hydroxamate derivative, exhibits anti-angiogenic activities via Src-homology-2-domain-containing protein tyrosine phosphatase 1Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.Proteomics identification of annexin A2 as a key mediator in the metastasis and proangiogenesis of endometrial cells in human adenomyosis.Through the looking glass: visualizing leukemia growth, migration, and engraftment using fluorescent transgenic zebrafishEllagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer.A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway.Antitumor activity of placenta-derived mesenchymal stem cells producing pigment epithelium-derived factor in a mouse melanoma model.Do anti-angiogenic cancer therapies increase risk of significant weight loss?A murine-human chimeric IgG antibody against vascular endothelial growth factor receptor 2 inhibits angiogenesis in vitro.Non-animal models of wound healing in cutaneous repair: In silico, in vitro, ex vivo, and in vivo models of wounds and scars in human skin.Utilizing Zebrafish to Identify Anti-(Lymph)Angiogenic Compounds for Cancer Treatment: Promise and Future Challenges.A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.The hormonal peptide Elabela guides angioblasts to the midline during vasculogenesis.α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway.Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.Cross-Talk between Cancer Cells and the Tumour Microenvironment: The Role of the 5-Lipoxygenase Pathway.The enzymatic activity of the VEGFR2 receptor for the biosynthesis of dinucleoside polyphosphates.An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs.Liver tumor models in transgenic zebrafish: an alternative in vivo approach to study hepatocarcinogenes.A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis.Improved osteogenesis and angiogenesis of magnesium-doped calcium phosphate cement via macrophage immunomodulation.Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model.Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor-specific inhibitor.Enhanced VEGF signalling mediates cerebral neovascularisation via downregulation of guidance protein ROBO4 in a rat model of diabetes.A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models.Live imaging of wound angiogenesis reveals macrophage orchestrated vessel sprouting and regression.
P2860
Q26796921-28FB6E65-2E6B-4F15-968E-F2D73AF726A6Q26997089-DF88FBF0-3E4F-4CDC-8193-45400E8C1EF2Q27320669-86DF5A7A-9A88-4952-9E93-5A727B5EE2ACQ33746225-A0FE12F8-4D15-4B2B-AB59-0D45426EEB89Q34030791-9667AFD1-0A28-4608-9C5C-695F26EE67DBQ34214323-AE15A07B-25F2-4EA8-BA1B-5177C90D4D21Q34332044-D5D26AB2-15A4-4D86-86DE-750A8AD203E1Q34346804-AF1F6369-6174-4C57-A666-54FFE883F55FQ34521999-9B6355D3-AA33-4A43-B80E-52671BE9372EQ34914220-C3CDBF59-ED3A-43AF-A3A3-8A9DB856B508Q35238403-53F1F693-CEAF-4315-9F68-E507695A271FQ35923178-4EB71273-0CA2-44F0-AFB0-EBCBB03AF93FQ36089898-F39D11BB-E919-440E-8D57-D25AF0455364Q36102145-611CC927-FAB8-4809-84E6-EBF76EC35DCAQ36131307-98BE31FC-F627-4853-8586-1459B226C1A8Q36279494-8D17B053-4BDA-4B0D-AA72-719CCC9B8863Q36772187-DF6B841C-952B-4C28-B7B0-706616063693Q36905311-89777114-9A20-4C60-AFB6-1D89D3E1E5B5Q38192670-905BA62B-7A3D-4805-95FA-8246D8BA7372Q38597921-E096F252-AE7D-47FF-B523-AC0909004C8FQ38766135-36E3C655-D881-41E0-A20A-CEC60F877588Q38833891-9E1A362F-A5E6-4960-AAF6-BFC44F9A277BQ38999290-CFAA9FBE-3A2F-481E-93B3-D95574D58562Q39002016-F7467DD8-4F69-48AB-BF3D-59F7DDD2A2B3Q39059452-CACB3581-4537-45FD-AA53-CEA660DEA1D6Q39091444-3FDA50D4-4C87-4D09-AEC0-3EA88F87CC6EQ39104480-C587ADA6-220B-44FF-8C87-17E786976EFCQ39157601-DAB2557E-4B91-44EE-83E5-EB794FB9C67CQ39394159-E9DABD7F-B498-4723-B2B8-73D06CA34179Q39678216-237A2725-5E8B-49FD-B3E8-BA1669D4FC18Q39679283-956D4DD7-09F2-49EE-811D-BABF0E751335Q40502779-CFCFD929-C43C-4CE4-A364-DB172759C1AAQ42777861-48EE3016-5D31-488D-8D18-7BC1518CC324Q47410775-C6FDC418-A9C4-4EED-BC56-A1A207732645Q47987289-F9124D3E-7F4D-4849-9259-61CC2C60E86BQ49416991-CDF7A31D-18D8-4EFC-8EFE-FCACD00FE8D7Q55517226-F19E1376-1EDF-4467-AC82-5CC040E14169
P2860
SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
SKLB1002, a novel potent inhib ...... esis and tumor growth in vivo.
@en
SKLB1002, a novel potent inhib ...... esis and tumor growth in vivo.
@nl
type
label
SKLB1002, a novel potent inhib ...... esis and tumor growth in vivo.
@en
SKLB1002, a novel potent inhib ...... esis and tumor growth in vivo.
@nl
prefLabel
SKLB1002, a novel potent inhib ...... esis and tumor growth in vivo.
@en
SKLB1002, a novel potent inhib ...... esis and tumor growth in vivo.
@nl
P2093
P1476
SKLB1002, a novel potent inhib ...... esis and tumor growth in vivo.
@en
P2093
Chengjian Zhao
Guobo Shen
Hongwei Tian
Hongxin Deng
Huanzhang Xie
Renlin Zheng
Senyi Deng
P304
P356
10.1158/1078-0432.CCR-10-3109
P407
P577
2011-05-27T00:00:00Z